
PRESS RELEASE

APEPTICO presents clinical results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2012 Annual Congress of the European Respiratory Society

31st August, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that it will present most recent clinical research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure at the 2012 Annual Congress of the European Respiratory Society.

At the 2012 Annual Congress of the European Respiratory Society (ERS) in Vienna (Austria, September 1st to 5th 2012), APEPTICO will present both phase I clinical and significant scientific research results of its inhalation therapy for prevention and treatment of Oedematous Respiratory Failure to the scientific community. The scientific advisory board of the ERS has appointed in total three contributions of APEPTICO to be presented at this major event.

In his presentation “Dose escalation study in healthy male subjects to investigate safety, tolerability and systemic exposure of orally inhaled single-doses of AP301” Dr. H. Pietschmann will summarise essential results of the outcome of the phase I clinical study of APEPTICO’s lead compound AP301. In this clinical study, the safety, tolerability and pharmacokinetic profile of AP301 was evaluated in a double-blind, randomized, placebo-controlled, parallel group study at the General Hospital in Vienna. Study participants received escalating doses of aerosolized AP301 in 6 dose groups between 0.07 mg/kg to 2 mg/kg AP301 per inhalation. This phase I trial demonstrated that orally inhaled AP301 was safe and well-tolerated by all study subjects. Dr. H. Fischer will give an overview of the pharmaceutical development work for the inhalation medicine in his presentation entitled “Pharmaceutical development of a liquid formulation for pulmonary application of a peptide”. Dr. S. Tzotzos will concentrate on the molecular target and mode of action of APEPTICO’s AP301 peptide in “ENaC activating effect of AP301 in type II alveolar cells isolated from dog, pig and rat lungs”.

APEPTICO’s lead peptide AP301 is currently subject to a Phase IIa clinical study in the Vienna General Hospital.

The ERS Congress is the largest international conference specialising in pulmonary medicine. It provides a unique forum where scientists and medical professionals from around the world have the opportunity to meet and exchange ideas and information in the field of respiratory medicine. The scientific programme of the ERS Congress aims to provide a perfect balance between clinical education and the latest scientific developments. The ERS Congress highlights key issues in the diagnosis, management and treatment of respiratory diseases, giving clinicians and research scientists the opportunity to report the latest findings in basic, clinical and population research.

Dr. Bernhard Fischer, CEO of APEPTICO commented: “I am pleased that the scientific organising committee of the ERS Annual Congress is giving us the opportunity to present the progress of our clinical drug development programme - the development of new medicines for prevention and treatment of Oedematous Respiratory Failure. Today no specific drug treatment exists for patients suffering from hyper-permeability-caused lung oedema.”

-- ENDS --

Notes to Editors:

About APEPTICO GmbH

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids general risks associated with gene- and cell-technologies. APEPTICO's makes use of its technology platforms PEPBASE™ and PEPSCREEN™ to significantly reduce cost and to shorten time to market.

About the AP301 peptide family

AP301 and derived peptides are synthetic molecules whose structures are based on the lectin-like domain of human Tumour Necrosis Factor alpha. AP301 peptides are water soluble and can be administered into the lung by oral inhalation. Formulated AP301 is easily nebulised and the resulting aerosol is composed of peptide/water droplets of diameter 4 µm or less. AP301 and derived peptides are designed for activation of the pulmonary epithelial sodium channel (ENaC). Activation of ENaC by AP301 peptides results an accelerated oedema clearance in the airspace. Comprehensive research and development conducted by APEPTICO has demonstrated that AP301 peptides are effective in animal models of pulmonary permeability oedema, pneumonia, influenza virus lung infection, Acute Lung Injury / Acute Respiratory Distress Syndrome and lung transplantation. AP301 has received Orphan Drug Designation by the EMA and by the FDA for various indications. Currently, AP301 is subject to a Phase IIa clinical study for the treatment of patients suffering from life-threatening oedematous respiratory failure.

About Oedematous Respiratory Failure

Respiratory failure occurs when the respiratory system fails in oxygenation and/or carbon dioxide elimination. Oedematous Respiratory Failure is caused by a massive and life-threatening pulmonary oedema. Pulmonary oedema occurs when fluid leaks from the pulmonary capillary network into the lung interstitium and alveoli. There are many possible causes of lung oedema, such as inhaling high concentrations of smoke, toxins, or oxygen; severe burns; blood infections; lung infections; or trauma to other parts of the body. Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are catastrophic forms of lung oedema.

Lungs contain alveoli, which are tiny air sacs where the oxygen is passed into the blood. During lung oedema, blood and fluid begin to leak into the alveoli. When this happens, oxygen cannot enter the alveoli, which means oxygen no longer passes into the blood. Because the lungs are inflamed and filled with fluid, the patient finds it increasingly difficult to breathe. The mortality rate of patients with pulmonary oedema in ALI/ARDS is 30% to 60% within 2 to 4 weeks.

Currently, no specific drug treatment exists for patients suffering from hyper-permeability-caused lung oedema.

Contact

Univ.- Doz. Dr. Bernhard Fischer, Chief Executive Officer

APEPTICO Forschung und Entwicklung GmbH

Mariahilfer Straße 136, A-1150 Vienna, Austria

T: +43-664-1432919

F: +43-1-25330337795

E-mail: b.fischer@apeptico.com

URL: www.apeptico.com

PRESS RELEASE

APEPTICO Initiates Phase II Trial with AP301 in Patients with Pulmonary Oedema

Vienna, Austria, June 29, 2012 - APEPTICO, a privately-held biotechnology company developing peptide drugs based on its PEPBASE™ discovery technology, today announced the initiation of a proof of concept study in male and female intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance.

AP301 is the first compound against respiratory failure caused by pulmonary oedema that activates lung oedema reabsorption and thus differs from the currently used anti-inflammatory treatment that often fails in patients with acute lung injury. The synthetic peptide AP301 activates alveolar liquid clearance (ALC) and prevents hyper-permeability in both endothelial and epithelial lung tissue. AP301 also prevents ischaemia reperfusion injury in the lower respiratory tract following lung transplantation.

The interventional, randomized, double-blind, placebo-controlled, parallel-group “proof of concept” study is conducted in Austria. Intensive care patients will receive doses of AP301 or matching placebo converted into an aerosol by state-of-the-art nebuliser technology over a period up to 7 days.

“We are very pleased that both the Ethics Committee and the Competent Authority approved our study only a few weeks after completion of the phase I clinical trial” said Bernhard Fischer, CEO of APEPTICO. “Treatment of oedematous respiratory failure represents an unmet medical need as no specific therapy or medicinal product has been approved so far for the prevention and treatment pulmonary oedema caused by hyper-permeability.”

Pressemitteilung

APEPTICO initiiert eine Phase II Studie mit AP301 in Patienten mit Lungenödem

Wien, Österreich, 29. Juli 2012 - APEPTICO, ein privates Biotechnologieunternehmen welches neue auf Peptiden basierende Medikamente entwickelt, hat heute den Beginn einer Konzeptstudie in männlichen und weiblichen Intensivpatienten bekannt gegeben, mit dem Ziel den klinischen Effekt von wiederholter oraler Inhalation von AP301 auf die Auflösung von Lungenödemen zu untersuchen.

AP301 ist der erste Wirkstoff gegen ein durch Lungenödem hervorgerufenes Atemversagen und unterscheidet sich daher wesentlich von Therapien, die primär gegen Entzündungen gerichtet sind, welche bisher in Patienten mit akutem Lungenschaden versagen.

Das synthetische Peptid AP301 aktiviert die Auflösung des Lungenödems und verhindert eine Hyperpermeabilität des Endothel- und Epithelgewebes der Lungebläschen. AP301 verhindert auch den Ischemischen Reperfusionsschaden nach Lungentransplantation.

Die interventionelle, randomisierte, doppelt-blinde, Placebo-kontrollierte Konzeptstudie wird in Österreich durchgeführt. Intensivpatienten werden entweder vernebeltes AP301 oder vernebeltes Placebo als Aerosol mittels Inhalation über einen Zeitraum von bis zu 7 Tagen erhalten.

“Wir sind sehr stolz, dass sowohl das Ethische Komitee als auch die zuständige Behörde unserer Studie zugestimmt haben, und dies nur wenige Wochen nach dem erfolgreichen Abschluss der Phase I Studie” sagte Bernhard Fischer, Geschäftsführer von APEPTICO. “Die Entwicklung einer Therapie zur Behandlung des durch Lungenödem bedingten Atemversagens stellt eine dringende medizinische Notwendigkeit dar, da es hier bisher keine ausreichende Therapie bzw. kein spezifisches Medikament zur Vermeidung und Behandlung des Hyperpermeabilitäts-Lungenödems gibt“.

- - ENDS - -

Notes to Editors:

About APEPTICO GmbH (www.apeptico.com)

APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules

Über APEPTICO Forschung und Entwicklung GmbH (www.apeptico.com)

APEPTICO Forschung und Entwicklung GmbH ist ein privates Biotechnologie Unternehmen in Österreich und entwickelt Peptidprodukte zur Behandlung von lebensbedrohenden und chronischen Krankheiten. Die Peptidprodukte entsprechen validierten und pharmakologisch aktiven Strukturen und Domänen von umfassend charakterisierten Proteinen und Protein-Arzneimitteln. Durch den Fokus auf synthetische Peptidmoleküle vermeidet APEPTICO das Risiko der Übertragung mikrobieller und viraler Infektionen. Im Vergleich zur rekombinanten Entwicklung von Biomolekülen können Kosten und Zeitdauer so deutlich verringert werden.

About AP301

AP301 is a synthetic molecule whose structure is based on the lectin-like domain of human Tumour Necrosis Factor alpha. AP301 is water soluble and can be administered into the lung by oral inhalation. Formulated AP301 is easily nebulised and the resulting aerosol is composed of peptide/water droplets of diameter 3 µm or less. AP301 has been designed for activation of the pulmonary epithelial sodium channel (ENaC). Activation of ENaC by AP301 peptides results an accelerated oedema clearance in the airspace in animal models of the pulmonary permeability oedema, pneumonia, influenza virus lung infection, Acute Lung Injury and lung transplantation. AP301 has received Orphan Drug Designation by the EMA and by the FDA for various indications. In 2011, AP301 has shown to be safe and well-tolerated by volunteer study subjects.

Über AP301

AP301 ist ein synthetisches Peptidmolekül, welches einer speziellen Struktur des menschlichen Tumor - Nekrosefaktors alpha (TNF- α) entspricht. Es ist wasserlöslich und kann durch Instillation oder Inhalation als Aerosol in die Lunge verabreicht werden. Gelöstes AP301 kann vernebelt werden, das resultierende Aerosol besteht aus feinsten Tröpfchen mit Durchmesser von 3 µm oder kleiner. AP301 wurde zur Aktivierung des pulmonalen epithelialen Natriumkanals (ENaC) entwickelt. Die Aktivierung von ENaC durch AP301 resultiert in verstärkter Auflösung eines Lungenödems in Tiermodellen des Permeabilitätsödems, der bakteriellen und viralen Lungenentzündung, des Akuten Lungenschadens und der Lungentransplantation. AP301 hat sowohl durch die EMA als auch durch die FDA eine Orphan Drug Designation erhalten. In einer klinischen Phase I –Studie im Jahr 2011 war AP301 sicher und gut verträglich.

Contact / Kontakt

Univ.- Doz. Dr. Bernhard Fischer, Chief Executive Officer
APEPTICO Forschung und Entwicklung GmbH
Mariahilferstraße 136, A-1150 Vienna, Austria
Mail: b.fischer@apeptico.com
URL: www.apeptico.com

PRESS RELEASE

APEPTICO completes a EUR 3.4 million financing round

16th May, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs, today announced completion of a EUR 3.4 million financing round. This equity financing combined existing and new private and institutional investors, as well as a research grant from the Austrian Research Promotion Agency (FFG).

A financing contribution of EUR 2 million is shared by institutional investors “The BioScience Venture Group”, “V+ GmbH & Co Fonds 2 KG” and “V+ GmbH & Co Fonds 3 KG”, and by private investors from Germany, Switzerland and the USA. Based on a previous and substantial capital increase in the year 2011, APEPTICO had already secured a research grant of EUR 1.4 million from the Austrian Research Promotion Agency (FFG) by the end of 2011.

Dr. Bernhard Fischer, CEO of APEPTICO commented: “We are delighted to have secured our third equity financing with an international syndicate of venture capital, private investors and the FFG. This round C financing enables us to continue the clinical development of our lead peptide AP301. AP301 will be assessed in a “proof of concept” study in intensive care patients to investigate the clinical effect of repetitive orally inhaled doses of AP301 on alveolar liquid clearance in acute lung injury.

PRESSE MITTEILUNG

APEPTICO schließt eine EUR 3,4 Mio. Finanzierungsrunde ab

16. Mai 2012, Wien, Österreich: APEPTICO Forschung und Entwicklung GmbH, ein Biotechnologieunternehmen welches neue auf Peptiden basierende Medikamente entwickelt, hat heute den erfolgreichen Abschluss einer EUR 3,4 Mio. Finanzierungsrunde bekannt gegeben. Die Beteiligungsinvestition vereint bereits bestehende und neue Investoren und eine Forschungsförderung durch die Österreichische Forschungsförderungsgesellschaft.

Der Finanzbeitrag von EUR 2 Millionen verteilt sich auf die Venture Capital Investoren “The BioScience Venture Group”, “V+ GmbH & Co Fonds 2 KG” and “V+ GmbH & Co Fonds 3 KG”, und auf private Investoren aus Deutschland, der Schweiz und den USA. Basierend auf einer früheren und substanziellen Investition im Jahr 2011, hatte APEPTICO bereits eine Forschungsförderung über EUR 1,4 Millionen durch die Österreichische Forschungsförderungsgesellschaft zum Ende 2011 erhalten.

Dr. Bernhard Fischer, Geschäftsführer der APEPTICO erklärt dazu: “Ich bin hochofreut, dass wir diese dritte Finanzierungsrunde mit einem Syndikat aus Venture Capital, Privatinvestoren und der FFG abschließen konnten. Diese Runde C Finanzierung ermöglicht es uns die klinische Entwicklung des Testarzneimittels AP301 voranzutreiben. AP301 wird in einer „Proof-of-Concept“ Studie an Intensivpatienten untersucht, um die Wirkung von wiederholten Inhalationsgaben von AP301 auf die Flüssigkeitsreduktion beim Akuten Lungenschaden zu untersuchen.

-- ENDS --

Notes to Editors:

About APEPTICO GmbH

APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules

Über APEPTICO Forschung und Entwicklung GmbH

APEPTICO Forschung und Entwicklung GmbH ist ein privates Biotechnologie Unternehmen in Österreich und entwickelt Peptidprodukte zur Behandlung von lebensbedrohenden und chronischen Krankheiten. Die Peptidprodukte entsprechen validierten und pharmakologisch aktiven Strukturen und Domänen von umfassend charakterisierten Proteinen und Protein-Arzneimitteln. Durch den Fokus auf synthetische Peptidmoleküle vermeidet APEPTICO das Risiko der Übertragung mikrobieller und viraler Infektionen. Im Vergleich zur rekombinanten Entwicklung von Biomolekülen können Kosten und Zeitdauer so deutlich verringert werden.

About AP301

AP301 is a synthetic molecule whose structure is based on the lectin-like domain of human Tumour Necrosis Factor alpha. AP301 is water soluble and can be administered into the lung by oral inhalation. Formulated AP301 is easily nebulised and the resulting aerosol is composed of peptide/water droplets of diameter 4 µm or less. AP301 has been designed for activation of the pulmonary epithelial sodium channel (ENaC). Activation of ENaC by AP301 peptides results an accelerated oedema clearance in the airspace in animal models of the pulmonary permeability oedema, pneumonia, influenza virus lung infection, Acute Lung Injury and lung transplantation. AP301 has received Orphan Drug Designation by the EMA and by the FDA for various indications. In 2011, AP301 has shown to be safe and well-tolerated by volunteer study subjects.

Über AP301

AP301 ist ein synthetisches Peptidmolekül, welches einer speziellen Struktur des menschlichen Tumor Nekrosefaktor alpha entspricht. Es ist wasserlöslich und kann in die Lunge durch Instillation oder als Aerosol verabreicht werden. Gelöstes AP301 kann vernebelt werden und das resultierende Aerosol besteht aus feinsten Tröpfchen mit Durchmesser von 4 µm oder kleiner. AP301 wurde zur Aktivierung des pulmonalen epithelialen Natriumkanals (ENaC) entwickelt. Die Aktivierung von ENaC durch AP301 resultiert in verstärkter Auflösung eines Lungenödems in Tiermodellen des Permeabilitätsödems, der bakteriellen und viralen Lungenentzündung, des Akuten Lungenschadens und der Lungentransplantation. AP301 hat durch die EMA und durch die FDA eine Orphan Drug Designation erhalten. AP301 war sicher und gut verträglich in einer Phase 1 klinischen Studie im Jahr 2011.

Contact / Kontakt

Univ.- Doz. Dr. Bernhard Fischer, Chief Executive Officer
APEPTICO Forschung und Entwicklung GmbH
Mariahilferstraße 136, A-1150 Vienna, Austria
Mail: b.fischer@apeptico.com
URL: www.apeptico.com

PRESS RELEASE

APEPTICO presents early clinical development results of its inhalation therapy for prevention and treatment of oedematous respiratory failure at the 2012 International Conference of the American Thoracic Society

10th May, 2012, Vienna, Austria: APEPTICO Forschung und Entwicklung GmbH, a biotechnology company developing novel peptide-based drugs for the treatment of life threatening lung diseases today announced that it will present early clinical development results of its inhalation therapy for prevention and treatment of oedematous respiratory failure at the 2012 International Conference of the American Thoracic Society.

At the 2012 International Conference of the American Thoracic Society (ATS) in San Francisco (California, USA, May 18th to 23rd), APEPTICO will present the current status of its development compound AP301 together with results of early clinical studies of AP301. APEPTICO develops AP301 for inhalation therapy for prevention and treatment of oedematous respiratory failure.

Dr. Bernhard Fischer, CEO of APEPTICO commented: “I am pleased that the scientific organising committee of the ATS International Conference is giving us the opportunity to present the progress of AP301 drug development - the development of a new medicines for prevention and treatment of oedematous respiratory failure. Today no specific drug treatment exists for patients suffering from hyper-permeability-caused lung oedema. We are very proud that our intensive and international collaborations with Professor Rudolf Lucas from the Georgia Health Sciences University (Augusta, USA) and with Professor Rosa Lemmens-Gruber from the University Vienna (Austria) enabled us to initiate and successfully complete first clinical studies with AP301.”

APEPTICO develops synthetic peptide drugs, based on the structural motif of the lectin-like domain of human tumour necrosis factor alpha (TNF-alpha), which activate the pulmonary epithelial sodium ion channel (ENaC) and thus accelerate pulmonary oedema reabsorption in life-threatening conditions such as pneumonia, influenza virus lung infection and Acute Lung Injury / Acute Respiratory Distress Syndrome. After completion of a series of pre-clinical studies in 2010 a phase I clinical trial in 2011 demonstrated that orally inhaled AP301 is safe and well-tolerated by study subjects. Currently, APEPTICO prepares for a phase IIa “proof of concept” clinical study to start in mid-2012.

With more than 15,000 members, the American Thoracic Society is a leading international medical association dedicated to advancing lung, critical care and sleep medicine.

The ATS International Conference aims to provide a perfect balance between clinical education and the latest scientific developments. The ATS ERS International Conference highlights key issues in the diagnosis, management and treatment of respiratory diseases, giving clinicians and research scientists the opportunity to report the latest findings in basic, clinical and population research.

-- ENDS --

Notes to Editors:

About APEPTICO GmbH

APEPTICO is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO's development platform PEPBASE™ combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements.

About the AP301 peptide family

AP301 and derived peptides are synthetic molecules whose structures are based on the lectin-like domain of human Tumour Necrosis Factor alpha. AP301 peptides are water soluble and can be administered into the lung by oral inhalation. Formulated AP301 is easily nebulised and the resulting aerosol is composed of peptide/water droplets of diameter 4 µm or less. AP301 and derived peptides are designed for activation of the pulmonary epithelial sodium channel (ENaC). Activation of ENaC by AP301 peptides results an accelerated oedema clearance in the airspace. Comprehensive research and development conducted by APEPTICO has demonstrated that AP301 peptides are effective in animal models of pulmonary permeability oedema, pneumonia, influenza virus lung infection, Acute Lung Injury / Acute Respiratory Distress Syndrome and lung transplantation. AP301 has received Orphan Drug Designation by the EMA and by the FDA for various indications. In 2011, AP301 has shown to be safe and well-tolerated by volunteer study subjects.

Oedematous Respiratory Failure

Respiratory failure occurs when the respiratory system fails in oxygenation and/or carbon dioxide elimination. Oedematous Respiratory Failure is caused by a massive and life-threatening pulmonary oedema. Pulmonary oedema occurs when fluid leaks from the pulmonary capillary network into the lung interstitium and alveoli. There are many possible causes of lung oedema, such as inhaling high concentrations of smoke, toxins, or oxygen; severe burns; blood infections; lung infections; or trauma to other parts of the body. Acute Lung Injury (ALI) and Acute Respiratory Distress Syndrome (ARDS) are catastrophic forms of lung oedema.

Lungs contain alveoli, which are tiny air sacs where the oxygen is passed into the blood. During lung oedema, blood and fluid begin to leak into the alveoli. When this happens, oxygen cannot enter the alveoli, which means oxygen no longer passes into the blood. Because the lungs are inflamed and filled with fluid, the patient finds it increasingly difficult to breathe. The mortality rate of patients with pulmonary oedema in ALI/ARDS is 30% to 60% within 2 to 4 weeks.

Currently, no specific drug treatment exists for patients suffering from hyper-permeability-caused lung oedema.

Contact

Univ.- Doz. Dr. Bernhard Fischer, Chief Executive Officer

APEPTICO Forschung und Entwicklung GmbH

Mariahilferstraße 136, A-1150 Vienna, Austria

T: +43-664-1432919; F: +43-664-1477280

Mail: b.fischer@apeptico.com

URL: www.apeptico.com

Press Communication

English

Vienna, Austria, 20th April, 2012: APEPTICO Forschung und Entwicklung GmbH has been nominated to present its innovative life-science projects at the “long night of research (“Lange Nacht der Forschung”) in Vienna, during the evening of April 27th, 2012. The “Lange Nacht der Forschung” aims to introduce state-of-the-art research results, innovations and inventions to the Austrian public. APEPTICO will present its peptide technology in the exhibition “The World of Innovation” at the Patent Office of Austria.

Most recently, APEPTICO’s patent “Prevention and Treatment of Hyperpermeability” was awarded the INVENTUM nomination based on a decision of a jury composed of experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology. APEPTICO’s invention ranks among the 10 most innovative inventions of the year 2011 in Austria.

Deutsch

Wien, Österreich, 20. April 2012: APEPTICO Forschung und Entwicklung GmbH wurde nominiert, seine innovativen Life-Science Projekte während der Langen Nacht der Forschung in Wien zu präsentieren. Das Ziel der Langen Nacht der Forschung ist es herausragende Forschungsergebnisse, Innovationen und Erfindungen den interessierten Bürgern Österreichs näher zu bringen. APEPTICO wird innerhalb der Ausstellung „Die Welt der Innovation“ seine Peptid-Technologie im Österreichischen Patentamt vorstellen.

Zu Beginn des Jahres wurde APEPTICO’s Patent “Vermeidung und Behandlung einer Hyperpermeabilität” durch die INVENTUM Nominierung ausgezeichnet, basierend auf der Entscheidung einer Jury aus Experten des Österreichischen Patentamtes und des Bundesministerium für Verkehr, Innovation und Technologie. APEPTICO’s Erfindung gehört zu den 10 innovativsten Erfindungen des Jahres 2011 in Österreich.

About APEPTICO GmbH

APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO's development platform PEPBASE™ combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements.

Über APEPTICO Forschung und Entwicklung GmbH

APEPTICO Forschung und Entwicklung GmbH ist ein privates Biotechnologie Unternehmen in Österreich und entwickelt Peptidprodukte zur Behandlung von lebensbedrohenden und chronischen Krankheiten. Die Peptidprodukte entsprechen validierten und pharmakologisch aktiven Strukturen und Domänen von umfassend charakterisierten Proteinen und Protein-Arzneimitteln. Durch den Fokus auf synthetische Peptidmoleküle vermeidet APEPTICO das Risiko der Übertragung mikrobieller und viraler Infektionen. Im Vergleich zur rekombinanten Entwicklung von Biomolekülen können Kosten und Zeitdauer so deutlich verringert werden. APEPTICOs Entwicklungsplattform PEPBASE™ vereint in sich strukturelle, funktionelle und klinische Daten von gut charakterisierten Proteinen und biologischen Arzneimitteln. Basierend auf vorklinischen und klinischen Daten, u.a. unerwünschten Reaktionen, Risikofaktoren und physiko-chemischen Informationen, wird für jedes Protein ein spezielles Profil abgeleitet, welches biologische und funktionelle Eigenschaften mit spezifischen Proteinstrukturen verbindet.

Contact / Kontakt

Univ.-Doz. Dr. Bernhard Fischer, Chief Executive Officer
APEPTICO Forschung und Entwicklung GmbH (www.apeptico.com)
Mariahilferstraße 136, A-1150 Vienna, Austria
T: +43-664-1432919, M: b.fischer@apeptico.com

ad hoc Communication

English

Vienna, Austria, 26th January, 2012- The patent “Prevention and Treatment of Hyperpermeability” invented and owned by [APEPTICO GmbH](#) ranks among the 10 most innovative inventions of the year 2011 in Austria. Today, APEPTICO’s patent AT 507 953 was awarded the INVENTUM nomination based on a decision of a jury composed of patent experts of the Austrian Patent Office and the Federal Ministry for Transport, Innovation and Technology.

The patent “Prevention and Treatment of Hyperpermeability” of APEPTICO Forschung und Entwicklung GmbH describes the circularised peptide “AP301” and its use for prophylactic and therapeutic treatment of damaged lung tissue. Injury of the barrier function of the pulmonary endothelial-epithelial cell layer leads to infiltration of blood and blood components into the airspace and formation of a pulmonary oedema. Fluid in the lung then strongly prevents normal gas exchange in the lung and such patients suffer from the life-threatening condition “Acute Lung Injury”. Currently, no specific drug treatment exists for patients suffering from hyperpermeability-caused lung oedema. Currently, APEPTICO’s peptide AP301 is subject to clinical studies.

Deutsch

Wien, Österreich, 26. Januar 2012- Das Patent “Vermeidung und Behandlung einer Hyperpermeabilität”, erfunden durch und im Besitz der [APEPTICO GmbH](#) gehört zu den 10 innovativsten Erfindungen des Jahres 2011 in Österreich. Am heutigen Tag wurde APEPTICO’s Patent AT 507 953 durch die INVENTUM Nominierung ausgezeichnet, basierend auf der Entscheidung einer Jury aus Patent Experten des Österreichischen Patentamtes und des Bundesministerium für Verkehr, Innovation und Technologie.

Das Patent „Vermeidung und Behandlung einer Hyperpermeabilität“ der APEPTICO Forschung und Entwicklung GmbH beschreibt das kreisförmige Peptid „AP301“ und dessen Verwendung zur prophylaktischen und therapeutischen Behandlung von verletztem Lungengewebe. Eine Verletzung der Barrierefunktion des Endothel-Epithel-Gewebes der Lunge führt zur Infiltration von Blut und Blutkomponenten in den Luftraum und zur Herausbildung eines Lungenödems. Die Flüssigkeit in der Lunge verhindert in der Folge den Gasaustausch in der Lunge und betroffene Patienten leiden an der lebensbedrohlichen Erkrankung „Akuter Lungenschaden“. Bisher gibt es keine Arzneimittel-spezifische Behandlungsmöglichkeit für Patienten mit einem durch Hyperpermeabilität ausgelösten Lungenödem. Derzeit wird APEPTICO’s Peptid AP301 in klinischen Studien untersucht.

About APEPTICO GmbH

APEPTICO Forschung und Entwicklung GmbH is a privately-held biotechnology company based in Austria, developing peptide-based products targeting chronic and life-threatening diseases. The peptide molecules correspond to validated, pharmacodynamic active structures and domains of well-known proteins and biopharmaceuticals. By concentrating on synthetically produced protein structures APEPTICO avoids any risk of transmitting microbial and viral infections. Development cost and time to market are significantly reduced if compared to the recombinant development process of biomolecules. APEPTICO's development platform PEPBASE™ combines structural, functional and clinical data from relevant biopharmaceuticals and well-characterised proteins. Based on preclinical and clinical data, including adverse reactions, risk factors and contraindications to be circumvented and supported by structural, biochemical and physicochemical data, for each relevant protein a specific profile is established that links biological & functional properties with discrete structural elements.

Über APEPTICO Forschung und Entwicklung GmbH

APEPTICO Forschung und Entwicklung GmbH ist ein privates Biotechnologie Unternehmen in Österreich und entwickelt Peptidprodukte zur Behandlung von lebensbedrohenden und chronischen Krankheiten. Die Peptidprodukte entsprechen validierten und pharmakologisch aktiven Strukturen und Domänen von umfassend charakterisierten Proteinen und Protein-Arzneimitteln. Durch den Fokus auf synthetische Peptidmoleküle vermeidet APEPTICO das Risiko der Übertragung mikrobieller und viraler Infektionen. Im Vergleich zur rekombinanten Entwicklung von Biomolekülen können Kosten und Zeitdauer so deutlich verringert werden. APEPTICOs Entwicklungsplattform PEPBASE™ vereint in sich strukturelle, funktionelle und klinische Daten von gut charakterisierten Proteinen und biologischen Arzneimitteln. Basierend auf vorklinischen und klinischen Daten, u.a. unerwünschten Reaktionen, Risikofaktoren und physiko-chemischen Informationen, wird für jedes Protein ein spezielles Profil abgeleitet, welches biologische und funktionelle Eigenschaften mit spezifischen Proteinstrukturen verbindet.

Contact / Kontakt

Univ.- Doz. Dr. Bernhard Fischer
Chief Executive Officer
APEPTICO Forschung und Entwicklung GmbH
Mariahilferstraße 136
A-1150 Vienna, Austria
T: +43-664-1432919
b.fischer@apeptico.com
www.apeptico.com